Ahn-gook Pharm to apply for diabetes treatment clinical trials in Europe
Aug. 17, 2016
[THE INVESTOR] Ahn-gook Pharmaceutical announced on Aug. 17 that it has completed a nonclinical study on UAI-101, an 11B-HSD1 inhibitor, and will apply for phase 1 clinical trials to the European Medicines Agency by the end of this year. This new drug candidate is a new type of therapy that will selectively inhibit 11B-HSD1, an enzyme that controls cortisol that regulates metabolism and thus can cause metabolic-related conditions including diabetes, obesity and dyslipidemia. Ahn-gook Pharmaceuti